Pure Global

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise - Trial NCT06323174

Access comprehensive clinical trial information for NCT06323174 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novo Nordisk A/S and is currently Recruiting. The study focuses on Type 2 Diabetes. Target enrollment is 180 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06323174
Phase 3
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06323174
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg Once Weekly Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Diet and Exercise

Study Focus

Type 2 Diabetes

Cagrilintide

Interventional

drug

Sponsor & Location

Novo Nordisk A/S

Huntington Park,Northridge,Santa Ana,Hollywood,Newton,Boston,Troy,Kingsport,Dallas,San Antonio,Shavano Park,Shavano Park,Newport News,Beijing,Nanjing,Zhenjiang,Ji'Nan,Debrecen,Nyíregyháza,Bergamo,Cata, China,Hungary,Italy,Poland,Saudi Arabia,Serbia,United States of America

Timeline & Enrollment

Phase 3

Mar 19, 2024

Nov 04, 2025

180 participants

Primary Outcome

Change in glycated haemoglobin (HbA1c)

Summary

This study will look at how much CagriSema helps participants with type 2 diabetes lower
 their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may
 not yet prescribe CagriSema. CagriSema will be compared to a dummy medicine (also called
 placebo) that has no effect on the body. Participants will get either CagriSema or dummy
 medicine. Which treatment participants get is decided by chance. For each participant, the
 study will last for about one year.

ICD-10 Classifications

Type 2 diabetes mellitus
Type 2 diabetes mellitus without complications
Type 2 diabetes mellitus with unspecified complications
Type 2 diabetes mellitus with other specified complications
Type 2 diabetes mellitus with multiple complications

Data Source

ClinicalTrials.gov

NCT06323174

Non-Device Trial